Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
CNBC - 2024-04-12T17:45:01.000Z

Analysts see weak trends for Trulicity, which led all Eli Lilly drugs in sales last year. But that won't keep the stock from going higher. Read this story